【摘要】 目的 观察奎的平治疗首发精神分裂症患者的疗效和安全性。方法对68例住院首发精神分裂症患者进行开放性临床治疗,疗程8w,根据患者的临床反应和耐受性调整剂量,平均治疗剂量295.5±2.05mg·d～1。分别在治疗前和治疗第1、2、4、6、8w末采用CGI、BPRS、TESS量表评估疗效及不良反应。结果 痊愈47例(69.1％),显著进步18例(26.5％),进步2例(2.9％),无效1例(1.5％),有效率95.4％。有12例(17.6％)患者出现轻微的头晕、嗜睡、体位性低血压、口干等不良反应少,较传统抗精神病药物低。结论 奎的平治疗首发精神分裂症安全,疗效确切,不良反应少。更多还原

【Abstract】 Objectve To assess the efficacy and safety of quetiapine in the treatment of first-episode schizophrenia . Methods 68 patients were enrolled into the open trial and treated with quetiapine for 8 weeks, the average dose was 295. 5 ±2. 05mg/d. The efficacy and side effects were assessed by CGI,BPRS,TESS before treatment and at the end of lst,2nd,4th,6th and 8th week of treatment. Results The effectual rate of quetiapine in the treatment of first-episode schizophrenia was 95. 4 %, incidence of side effects was lower than that of traditional antipsychotics.. Conclusion Quetiapine is an effective and safe drug in the treatment of first-episode schizophrenia and its side effects fewer.更多还原